



GOV. MSG. NO. 1154

EXECUTIVE CHAMBERS
HONOLULU

NEIL ABERCROMBIE
GOVERNOR

April 28, 2014

The Honorable Donna Mercado Kim,
President
and Members of the Senate
Twenty-Seventh State Legislature
State Capitol, Room 409
Honolulu, Hawaii 96813


The Honorable Joseph M. Souki,
Speaker and Members of the
House of Representatives
Twenty-Seventh State Legislature
State Capitol, Room 431
Honolulu, Hawaii 96813

Dear President Kim, Speaker Souki, and Members of the Legislature:

This is to inform you that on April 28, 2014, the following bill was signed into law:

SB2882 SD2 HD2

RELATING TO THE UNIFORM CONTROLLED
SUBSTANCES ACT
ACT 054 (14)

Sincerely,


NEIL ABERCROMBIE
Governor, State of Hawaii

RECEIVED
THE SENATE
CLERK'S OFFICE
STATE OF HAWAII

'14 APR 30 AIO :22

RECEIVED
SENATE
OFFICE OF THE PRESIDENT

'14 APR 29 AIO :02

A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. Section 329-14, Hawaii Revised Statutes, is
2 amended as follows:

3 1. By amending subsection (d) to read:

4 "(d) Any material, compound, mixture, or preparation that
5 contains any quantity of the following hallucinogenic
6 substances, their salts, isomers, and salts of isomers, unless
7 specifically excepted, whenever the existence of these salts,
8 isomers, and salts of isomers is possible within the specific
9 chemical designation:

- 10 (1) Alpha-ethyltryptamine (AET);
11 (2) 2,5-dimethoxy-4-ethylamphetamine (DOET);
12 (3) 2,5-dimethoxyamphetamine (2,5-DMA);
13 (4) 3,4-methylenedioxy amphetamine;
14 (5) 3,4-methylenedioxymethamphetamine (MDMA);
15 (6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-
16 MDA);
17 (7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);
18 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;



- 1 (9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
- 2 (10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
- 3 (11) 3,4,5-trimethoxy amphetamine;
- 4 (12) Bufotenine;
- 5 (13) 4-methoxyamphetamine (PMA);
- 6 (14) Diethyltryptamine;
- 7 (15) Dimethyltryptamine;
- 8 (16) 4-methyl-2,5-dimethoxy-amphetamine;
- 9 (17) Gamma hydroxybutyrate (GHB) (some other names include
- 10 gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-
- 11 hydroxybutanoic acid; sodium oxybate; sodium
- 12 oxybutyrate);
- 13 (18) Ibogaine;
- 14 (19) Lysergic acid diethylamide;
- 15 (20) Marijuana;
- 16 (21) Parahexyl;
- 17 (22) Mescaline;
- 18 (23) Peyote;
- 19 (24) N-ethyl-3-piperidyl benzilate;
- 20 (25) N-methyl-3-piperidyl benzilate;
- 21 (26) Psilocybin;
- 22 (27) Psilocyn;



- 1 (28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
2 (29) Ethylamine analog of phencyclidine (PCE);
3 (30) Pyrrolidine analog of phencyclidine (PCPy, PHP);
4 (31) Thiophene analog of phencyclidine (TCP; TCP);
5 (32) Gamma-butyrolactone, including butyrolactone;
6 butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone
7 dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone;
8 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-
9 hydroxybutyric acid lactone; 3-hydroxybutyric acid
10 lactone and 4-hydroxybutanoic acid lactone with
11 Chemical Abstract Service number 96-48-0 when any such
12 substance is intended for human ingestion;
13 (33) 1,4 butanediol, including butanediol; butane-1,4-diol;
14 1,4- butylenes glycol; butylene glycol; 1,4-
15 dihydroxybutane; 1,4- tetramethylene glycol;
16 tetramethylene glycol; tetramethylene 1,4- diol with
17 Chemical Abstract Service number 110-63-4 when any
18 such substance is intended for human ingestion;
19 (34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7),
20 its optical isomers, salts, and salts of isomers;
21 (35) N-benzylpiperazine (BZP; 1-benzylpiperazine) its
22 optical isomers, salts, and salts of isomers;



- 1 (36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its
2 optical isomers, salts, and salts of isomers;
- 3 (37) Alpha-methyltryptamine (AMT), its isomers, salts, and
4 salts of isomers;
- 5 (38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its
6 isomers, salts, and salts of isomers;
- 7 (39) Salvia divinorum;
- 8 (40) Salvinorin A;
- 9 (41) Divinorin A; [~~and~~]
- 10 (42) 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some
11 trade or other names: 5-methoxy-3-[2-
12 (dimethylamino)ethyl]indole; 5-MeO-DMT) [-];
- 13 (43) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
- 14 (44) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
- 15 (45) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
- 16 (46) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
- 17 (47) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-
18 2);
- 19 (48) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine
20 (2C-T-4);
- 21 (49) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
- 22 (50) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);



- 1 (51) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
2 (52) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
3 methoxybenzyl)ethanamine, its optical, positional, and
4 geometric isomers, salts, and salts of isomers (Other
5 names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
6 (53) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-
7 methoxybenzyl)ethanamine, its optical, positional, and
8 geometric isomers, salts, and salts of isomers (Other
9 names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); and
10 (54) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
11 methoxybenzyl)ethanamine, its optical, positional, and
12 geometric isomers, salts, and salts of isomers (Other
13 names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)."

14 2. By amending subsection (g) to read:

15 "(g) Any of the following cannabinoids, their salts,
16 isomers, and salts of isomers, unless specifically excepted,
17 whenever the existence of these salts, isomers, and salts of
18 isomers is possible within the specific chemical designation:

- 19 (1) Tetrahydrocannabinols; meaning tetrahydrocannabinols
20 naturally contained in a plant of the genus Cannabis
21 (cannabis plant), as well as synthetic equivalents of
22 the substances contained in the plant, or in the



1 resinous extractives of Cannabis, sp. or synthetic
2 substances, derivatives, and their isomers with
3 similar chemical structure and pharmacological
4 activity to those substances contained in the plant,
5 such as the following: Delta 1 cis or trans
6 tetrahydrocannabinol, and their optical isomers; Delta
7 6 cis or trans tetrahydrocannabinol, and their optical
8 isomers; and Delta 3,4 cis or trans-
9 tetrahydrocannabinol, and its optical isomers (since
10 nomenclature of these substances is not
11 internationally standardized, compounds of these
12 structures, regardless of numerical designation of
13 atomic positions, are covered);

- 14 (2) Naphthoylindoles; meaning any compound containing a
15 3-(1-naphthoyl) indole structure with substitution at
16 the nitrogen atom of the indole ring by a alkyl,
17 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
18 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
19 ethyl group, whether or not further substituted in the
20 indole ring to any extent and whether or not
21 substituted in the naphthyl ring to any extent;



- 1 (3) Naphthylmethylindoles; meaning any compound containing
2 a 1H-indol-3-yl-(1-naphthyl) methane structure with
3 substitution at the nitrogen atom of the indole ring
4 by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
5 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
6 2-(4-morpholinyl) ethyl group whether or not further
7 substituted in the indole ring to any extent and
8 whether or not substituted in the naphthyl ring to any
9 extent;
- 10 (4) Naphthoylpyrroles; meaning any compound containing a
11 3-(1-naphthoyl) pyrrole structure with substitution at
12 the nitrogen atom of the pyrrole ring by a alkyl,
13 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
14 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
15 ethyl group whether or not further substituted in the
16 pyrrole ring to any extent, whether or not substituted
17 in the naphthyl ring to any extent;
- 18 (5) Naphthylmethylindenes; meaning any compound containing
19 a naphthylideneindene structure with substitution at
20 the 3-position of the indene ring by a alkyl,
21 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
22 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)



- 1 ethyl group whether or not further substituted in the
2 indene ring to any extent, whether or not substituted
3 in the naphthyl ring to any extent;
- 4 (6) Phenylacetylindoles; meaning any compound containing a
5 3-phenylacetylindole structure with substitution at
6 the nitrogen atom of the indole ring by a alkyl,
7 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
8 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
9 ethyl group whether or not further substituted in the
10 indole ring to any extent, whether or not substituted
11 in the phenyl ring to any extent;
- 12 (7) Cyclohexylphenols; meaning any compound containing a
13 2-(3-hydroxycyclohexyl) phenol structure with
14 substitution at the 5-position of the phenolic ring by
15 a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
16 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
17 2-(4-morpholinyl) ethyl group whether or not
18 substituted in the cyclohexyl ring to any extent;
- 19 (8) Benzoylindoles; meaning any compound containing a
20 3-(benzoyl) indole structure with substitution at the
21 nitrogen atom of the indole ring by a alkyl,
22 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,



- 1 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
2 ethyl group whether or not further substituted in the
3 indole ring to any extent and whether or not
4 substituted in the phenyl ring to any extent;
- 5 (9) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
6 pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
7 naphthalenylmethanone (another trade name is WIN
8 55,212-2);
- 9 (10) (6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-
10 methyloctan-2-yl)-6a,7,10,10a-
11 tetrahydrobenzo[c]chromen-1-ol (other trade names are:
12 HU-210 and HU-211); [~~and~~]
- 13 (11) Tetramethylcyclopropanoylindoles; meaning any compound
14 containing a 3-tetramethylcyclopropanoylindole
15 structure with substitution at the nitrogen atom of
16 the indole ring by an alkyl, haloalkyl, cyanoalkyl,
17 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
18 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,
19 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
20 morpholinyl)methyl, or tetrahydropyranylmethyl group,
21 whether or not further substituted in the indole ring



- 1 to any extent and whether or not substituted in the
2 tetramethylcyclopropyl ring to any extent[-];
- 3 (12) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
4 its optical, positional, and geometric isomers, salts,
5 and salts of isomers (Other names: APINACA, AKB48);
- 6 (13) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its
7 optical, positional, and geometric isomers, salts, and
8 salts of isomers (Other names: PB-22; QUPIC);
- 9 (14) Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-
10 carboxylate, its optical, positional, and geometric
11 isomers, salts, and salts of isomers (Other names: 5-
12 fluoro-PB-22; 5F-PB-22);
- 13 (15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
14 fluorobenzyl)-1H-indazole-3-carboxamide, its optical,
15 positional, and geometric isomers, salts, and salts of
16 isomers (Other names: AB-FUBINACA); and
- 17 (16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
18 indazole-3-carboxamide, its optical, positional, and
19 geometric isomers, salts, and salts of isomers (Other
20 names: ADB-PINACA)."



1 SECTION 2. Section 329-18, Hawaii Revised Statutes, is
2 amended by amending subsection (c) to read as follows:

3 "(c) Depressants. Unless listed in another schedule, any
4 material, compound, mixture, or preparation containing any
5 quantity of the following substances having a depressant effect
6 on the central nervous system:

- 7 (1) Any compound, mixture, or preparation containing
8 amobarbital, secobarbital, pentobarbital, or any salt
9 thereof and one or more other active medicinal
10 ingredients which are not listed in any schedule;
- 11 (2) Any suppository dosage form containing amobarbital,
12 secobarbital, pentobarbital, or any salt of any of
13 these drugs and approved by the Food and Drug
14 Administration for marketing only as a suppository;
- 15 (3) Any substance that contains any quantity of a
16 derivative of barbituric acid or any salt thereof,
17 including the substance butalbital;
- 18 (4) Chlorhexadol;
- 19 (5) Embutramide (Tributame);
- 20 (6) Ketamine, its salts, isomers, and salts of isomers,
21 also known as (+ or -)-2-(2-chlorophenyl)-2-
22 (methylamino)-cyclohexanone;



- 1 (7) Lysergic acid;
- 2 (8) Lysergic acid amide;
- 3 (9) Methyprylon;
- 4 (10) Sulfondiethylmethane;
- 5 (11) Sulfonethylmethane;
- 6 (12) Sulfonmethane;
- 7 (13) Tiletamine/Zolazepam (Telazol, 2-(ethylamino)-2-(
8 thienyl)-cyclohexanone, flupyrzapon) or any salts
9 thereof; [and]
- 10 (14) Gamma hydroxybutyric acid and its salts, isomers, and
11 salts of isomers that are contained in a drug product
12 for which an application has been approved under
13 section 505 of the federal Food, Drug, and Cosmetic
14 Act [-];
- 15 (15) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-
16 dihydropyridin-3-yl)benzotrile], including its
17 salts, isomers, and salts of isomers; and
- 18 (16) Alfaxalone 5[alpha]-pregnan-3[alpha]-ol-11,20-dione,
19 including its salts, isomers, and salts of isomers."

20 SECTION 3. Section 329-20, Hawaii Revised Statutes, is
21 amended by amending subsection (d) to read as follows:




1 "(d) Stimulants. Unless listed in another schedule, any
2 material, compound, mixture, or preparation which contains any
3 quantity of the following substances having a stimulant effect
4 on the central nervous system, including its salts, isomers, and
5 salts of such isomers whenever the existence of such salts,
6 isomers, and salts of isomers is possible within the specific
7 chemical designation:

- 8 (1) Cathine ((+)-norpseudoephedrine);
- 9 (2) Diethylpropion;
- 10 (3) Fencamfamin;
- 11 (4) Fenproporex;
- 12 (5) Mazindol;
- 13 (6) Mefenorex;
- 14 (7) Modafinil;
- 15 (8) Phentermine;
- 16 (9) Pemoline (including organometallic complexes and
17 chelates thereof);
- 18 (10) Pipradrol;
- 19 (11) Sibutramine; [~~and~~]
- 20 (12) SPA (1-dimethylamino-1,2-diphenylethane,
21 lefetamine) [~~-~~]; and
- 22 (13) Lorcaserin."



1 SECTION 4. Statutory material to be repealed is bracketed
2 and stricken. New statutory material is underscored.
3 SECTION 5. This Act shall take effect upon its approval.

APPROVED this 28 day of APR, 2014



GOVERNOR OF THE STATE OF HAWAII